HC Wainwright Reiterates “$5.00” Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM)
Alimera Sciences, Inc. (NASDAQ:ALIM) has been assigned a $5.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 218.47% from the stock’s current price.
Other equities analysts have also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They issued a “buy” rating and a $4.00 price target on the stock. Cowen and Company reaffirmed a “buy” rating and issued a $3.00 price target on shares of Alimera Sciences in a research report on Tuesday, July 11th. Zacks Investment Research raised shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, July 10th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Alimera Sciences presently has an average rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences (NASDAQ:ALIM) traded up 4.67% during mid-day trading on Friday, hitting $1.57. The company had a trading volume of 382,253 shares. The firm’s market capitalization is $101.89 million. Alimera Sciences has a 12-month low of $1.03 and a 12-month high of $2.40. The company’s 50 day moving average price is $1.42 and its 200-day moving average price is $1.38.
Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. During the same period in the previous year, the business posted ($0.17) EPS. Alimera Sciences’s revenue was up 8.3% compared to the same quarter last year. On average, analysts forecast that Alimera Sciences will post ($0.21) EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in ALIM. KCG Holdings Inc. boosted its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. Kennedy Capital Management Inc. purchased a new position in Alimera Sciences during the first quarter valued at approximately $467,000. Finally, JW Asset Management LLC boosted its position in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares in the last quarter. 43.58% of the stock is currently owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.